Search results for "Dopamine"

showing 10 items of 660 documents

Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant

1998

Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions and to block the formation of conditioned place preferences; these effects are reversed by chronic treatment with tricyclic or atypical antidepressant drugs. The present study was designed to evaluate the antidepressant-like activity in this model of flibaserin (BIMT-17), a novel serotonergic agent with 5-HT1A receptor agonist and 5-HT2 receptor antagonist properties. Two experiments were conducted, using rats (experiment 1) and mice (experiment 2). In experiment 1, decreases in sucrose intake were seen in rats exposed to chronic mild stress, but the effect was unr…

MaleAgonistSucrosemedicine.medical_specialtyQuinpirolemedicine.drug_classMotor ActivityMiceSerotonin AgentsQuinpiroleDopamine receptor D3Dopamine receptor D2Internal medicineSalicylamidesmedicineAnimalsRats WistarPharmacologyRacloprideFluoxetinebusiness.industryBody WeightFeeding BehaviorConditioned place preferenceRatsEndocrinologyRacloprideAntidepressive Agents Second-GenerationConditioning OperantDopamine AntagonistsFlibanserinBenzimidazolesbusinessStress Psychologicalmedicine.drugEuropean Journal of Pharmacology
researchProduct

Shell/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens

2008

The mu- and delta-opioid receptors located at the terminal level in nucleus accumbens are involved in the opiate modulation of dopamine release in this brain area. However, recent studies suggest that the effects of opioid drugs on the core subregion of nucleus accumbens may completely differ from those observed in the shell. We used in vivo microdialysis to simultaneously apply selective mu- and delta-opioid receptor agonists and to measure extracellular levels of dopamine in three subregions of the accumbens, namely shell, core, and the transition zone between them. The regional analysis of these subregions of the accumbens demonstrated that basal levels of dopamine and its metabolites we…

MaleAgonistTime FactorsEnkephalinmedicine.drug_classDopamineMicrodialysisReceptors Opioid muPharmacologyNucleus accumbensNucleus Accumbensδ-opioid receptorCellular and Molecular Neurosciencechemistry.chemical_compoundDopamine receptor D1DopamineReceptors Opioid deltamedicineAnimalsRats WistarPharmacologyDopaminergicHomovanillic AcidEnkephalin Ala(2)-MePhe(4)-Gly(5)-RatsAnalgesics OpioidDAMGOchemistry34-Dihydroxyphenylacetic AcidEnkephalin D-Penicillamine (25)-medicine.drugNeuropharmacology
researchProduct

Specific Hippocampal Interneurons Shape Consolidation of Recognition Memory

2020

Summary A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal interneurons determines episodic-like memory consolidation by linking dopamine D1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB1Rs in D1-positive cells (D1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB1Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potenti…

MaleAnimals CB1 receptor D1 receptor Dopamine Endocannabinoid system GABA Hippocampus Interneurons Long-term potentiation Male Memory Mice Novel object recognition Recognition PsychologyCB1 receptorCB1 cannabinoid receptorsD(1) receptorhippocampus[SDV]Life Sciences [q-bio]D1 receptorneuronsCB(1) receptorArticleCA1informationMiceGABAMemoryAnimalsendocannabinoid systemlong-term potentiationinterneuronsmusculoskeletal neural and ocular physiologyRecognition Psychologyepisodic memoryinhibition[SDV] Life Sciences [q-bio]modulationnervous systemdopamineLTPnovel object recognition memory
researchProduct

Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET

2015

Dopamine D2/3 receptor (D2/3R) agonist PET tracers are better suited for the imaging of synaptic dopaminergic neurotransmission than D2/3R antagonists and may also offer the opportunity to study in vivo the high-affinity state of D2/3R (D2/3RHigh). With the aim to develop 18F-labeled D2/3R agonists suitable for widespread clinical application, we report here on the synthesis and in vitro and in vivo evaluation of a D2/3R agonist ligand from the aminomethyl chromane (AMC) class-(R)-2-[(4- 18Fluorobenzylamino)methyl]chroman-7-ol (18F-AMC20). Methods: In vitro affinities of AMC20 toward dopaminergic receptor subtypes were measured in membrane homogenates prepared from HEK293 cells expressing h…

MaleBenzylaminesChemistry Techniques SyntheticPharmacologyLigandsRats Sprague-DawleyCricetinaeBINDINGRadioligandIN-VIVORacloprideRadiochemistryChemistryDopaminergicBrainStereoisomerismLigand (biochemistry)SERIESADDICTIONDopamine receptorDopamine AgonistsHIGH-AFFINITY STATEmedicine.drugAgonistmedicine.drug_classDRUG-ABUSECHO CellsPOSITRON-EMISSION-TOMOGRAPHYCricetulusFIn vivoDopamine receptor D2medicineAnimalsHumansRadiology Nuclear Medicine and imagingBenzopyransChromansReceptors Dopamine D2F-18Receptors Dopamine D3Biological TransportAgonist tracerRatsKineticsHEK293 CellsPETDopamine receptorRaclopridePositron-Emission TomographyRADIOTRACERSYSTEMJournal of Nuclear Medicine
researchProduct

[(11)C]PR04.MZ, a promising DAT ligand for low concentration imaging: Synthesis, efficient (11)C-O-methylation and initial small animal PET studies.

2009

PR04.MZ was designed as a highly selective dopamine transporter inhibitor, derived from natural cocaine. Its binding profile indicates that [{sup 11}C]PR04.MZ may be suited as a PET radioligand for the non-invasive exploration of striatal and extrastriatal DAT populations. As a key feature, its structural design facilitates both, labelling with fluorine-18 at its terminally fluorinated butynyl moiety and carbon-11 at its methyl ester function. The present report concerns the efficient [{sup 11}C]MeI mediated synthesis of [{sup 11}C]PR04.MZ from an O-desmethyl precursor trifluoroacetic acid salt with Rb{sub 2}CO{sub 3} in DMF in up to 95 {+-} 5% labelling yield. A preliminary {mu}PET-experim…

MaleBiodistributionFluorine RadioisotopesTime FactorsStereochemistryClinical BiochemistryPharmaceutical ScienceBiochemistryChemical synthesisMethylationRats Sprague-Dawleychemistry.chemical_compoundRadioligand AssayDrug DiscoveryRadioligandTrifluoroacetic acidMoietyAnimalsMolecular BiologyDopamine transporterCarbon IsotopesDopamine Plasma Membrane Transport ProteinsbiologyBicyclic moleculeOrganic ChemistryBrainLigand (biochemistry)Magnetic Resonance ImagingRatschemistryModels ChemicalDrug DesignPositron-Emission Tomographybiology.proteinMolecular MedicineAzabicyclo CompoundsTropanesBioorganicmedicinal chemistry letters
researchProduct

Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice.

2007

Although the rewarding effects of 3,4-methylenedioxy-metamphetamine (MDMA) have been demonstrated in self-administration and conditioned place preference (CPP) procedures, its addictive potential (ie, the vulnerability to relapse, measured by its ability to induce reinstatement of an extinguished response), remains poorly understood. In this study, the effects of MDMA (5, 10, and 20 mg/kg) on the acquisition, extinction and reinstatement of CPP were evaluated in mice, using two different protocols during acquisition of CPP. In the first experiment, animals were trained using a two-session/day schedule (MDMA and saline for 4 consecutive days), whereas in the second experiment, they were trai…

MaleBiogenic AminesReinforcement ScheduleN-Methyl-34-methylenedioxyamphetamineStriatumPharmacologyExtinction Psychologicalchemistry.chemical_compoundMiceRewardDopaminemental disordersmedicineAnimalsNeurotransmitterPharmacologyBrain ChemistryAnalysis of VarianceBehavior AnimalDose-Response Relationship DrugMDMAExtinction (psychology)Conditioned place preferenceRatsPsychiatry and Mental healthchemistryAnimals NewbornAnesthesiaHallucinogensConditioning OperantSerotoninAnalysis of variancePsychologypsychological phenomena and processesmedicine.drugNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system

2000

alpha-Synuclein (alpha-Syn) is a 14 kDa protein of unknown function that has been implicated in the pathophysiology of Parkinson's disease (PD). Here, we show that alpha-Syn-/- mice are viable and fertile, exhibit intact brain architecture, and possess a normal complement of dopaminergic cell bodies, fibers, and synapses. Nigrostriatal terminals of alpha-Syn-/- mice display a standard pattern of dopamine (DA) discharge and reuptake in response to simple electrical stimulation. However, they exhibit an increased release with paired stimuli that can be mimicked by elevated Ca2+. Concurrent with the altered DA release, alpha-Syn-/- mice display a reduction in striatal DA and an attenuation of …

MaleCalbindinsNeuroscience(all)DopamineDopamine AgentsLong-Term PotentiationPresynaptic TerminalsSynucleinsGene ExpressionGlutamic AcidSubstantia nigraNerve Tissue ProteinsNeurotransmissionMotor ActivityHippocampusSynaptic TransmissionReuptakechemistry.chemical_compoundMiceS100 Calcium Binding Protein GDopamineDopaminergic CellmedicineAnimalsAutoreceptorsAlpha-synucleinMice KnockoutNeuronsGeneral NeuroscienceRab3A GTP-Binding ProteinCorpus Striatumrab3A GTP-Binding Proteinnervous system diseasesMice Inbred C57BLSubstantia NigraAmphetaminechemistrynervous systemalpha-SynucleinCalciumFemaleBeta-synucleinNeuroscienceLocomotionmedicine.drug
researchProduct

Protective activation of the endocannabinoid system during ischemia in dopamine neurons

2006

Endocannabinoids act as neuroprotective molecules promptly released in response to pathological stimuli. Hence, they may represent one component of protection and/or repair mechanisms mobilized by dopamine (DA) neurons under ischemia. Here, we show that the endocannabinoid 2-arachidonoyl-glycerol (2-AG) plays a key role in protecting DA neurons from ischemia-induced altered spontaneous activity both in vitro and in vivo. Accordingly, neuroprotection can be elicited through moderate cannabinoid receptor type-1 (CB1) activation. Conversely, blockade of endocannabinoid actions through CB1 receptor antagonism worsens the outcome of transient ischemia on DA neuronal activity. These findings indi…

MaleCannabinoid receptorDopaminePharmacologyBrain IschemiaMidbrainRats Sprague-DawleyMicePiperidinesReceptor Cannabinoid CB1IschemiaPremovement neuronal activityReceptorMice KnockoutNeuronsmusculoskeletal neural and ocular physiologyEndocannabinoid systemCB1NeuroprotectionElectrophysiologyNeurologylipids (amino acids peptides and proteins)Rimonabantpsychological phenomena and processesmedicine.drugSignal TransductionMorpholinesIschemiaArachidonic AcidsBiologyIn Vitro TechniquesNaphthalenesNeuroprotectionAmidohydrolasesGlycerideslcsh:RC321-571DopamineCannabinoid Receptor ModulatorsmedicineAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryEndocannabinoidVentral Tegmental Areamedicine.diseaseBlockadeBenzoxazinesRatsnervous systemPyrazolesNeuroscienceEndocannabinoidsNeurobiology of Disease
researchProduct

Effects of Fenoldopam on Intracranial Pressure and Hemodynamic Variables at Normal and Elevated Intracranial Pressure in Anesthetized Pigs

1994

Fenoldopam (FE), a dopamine DA1-receptor agonist, has been introduced for treatment of arterial hypertension and heart failure and for preservation of renal function. Vasodilators are generally assumed to affect all vascular beds including the cerebral circulation. We have evaluated effects of FE-induced (4 micrograms.kg-1.min-1) arterial hypotension on intracranial pressure (ICP) and intraocular pressure (IOP) under conditions of normal and increased intracranial elastance. ICP and IOP responses to hypertension were tested by infusion of angiotensin II (15 micrograms.kg-1.min-1), and the response to hypercapnia was tested by elimination and reintegration of soda lime canisters in the breat…

MaleCentral Venous PressureIntracranial PressureFenoldopamSwineDopamine AgentsHemodynamicsBlood PressureAnesthesia GeneralFenoldopamCerebral autoregulationHypercapniaCerebral circulationCerebrospinal fluidHeart RateAnimalsMedicinePulmonary Wedge PressureAntihypertensive AgentsIntraocular PressureIntracranial pressurePseudotumor CerebriDose-Response Relationship Drugbusiness.industryAngiotensin IIHemodynamicsAngiotensin IIAnesthesiology and Pain MedicineCerebrovascular CirculationAnesthesiaHypertensionFemaleOcular HypertensionVascular ResistanceSurgery2345-Tetrahydro-78-dihydroxy-1-phenyl-1H-3-benzazepineNeurology (clinical)medicine.symptombusinessHypercapniamedicine.drugJournal of Neurosurgical Anesthesiology
researchProduct

Interaction of morphine and haloperidol on agonistic and motor behaviors of male mice.

1997

To further clarify the interaction between opioid and dopaminergic systems, the effects of simultaneous administration of morphine hydrochloride (1.25 or 2.5 mg/kg) and haloperidol (0.1 mg/kg) on aggressive behavior of male mice were explored. Isolated male mice (experimental animals) were confronted in a neutral area with anosmic, group-housed consepecifics (standard opponents) 30 min after injection of both compounds, and aggression was evaluated by estimation of times allocated to 11 different behavioral categories. In the first experiment (which functioned as a pilot study), the two doses of morphine were explored. In the second one, incorporating a more complete experimental design, on…

MaleClinical BiochemistryMice Inbred StrainsPharmacologyMotor ActivityToxicologyBiochemistryBehavioral NeuroscienceMicemedicineHaloperidolAgonistic behaviourAnimalsDrug InteractionsSocial BehaviorBiological PsychiatryPharmacologyMorphineAggressionDopaminergicAntagonistDrug interactionGroomingAnalgesics OpioidOpioidMorphineExploratory BehaviorDopamine AntagonistsHaloperidolmedicine.symptomPsychologyAgonistic Behaviormedicine.drugPharmacology, biochemistry, and behavior
researchProduct